CHI Announces a Pre-clinical Assessment for Prediction of Clinical Success for Cancer Biologics

A roundtable discussion during the Cancer Biologics Conference at the Tri-Conference. Moderatored by: Gary Starling, Ph.D., Director, GPRD Discovery, Oncology Biologics, Abbott Biotherapeutics Corp.
 
Jan. 19, 2012 - PRLog -- NEEDHAM, MASS. – Cambridge Healthtech Institute announces Pre-clinical Assessment for Prediction of Clinical Success for Cancer Biologics. This roundtable discussion will be held during  during the Cancer Biologics Conference at the Tri-Conference.

Featuring over 25 presentations, this unique three-day conference presents advances in antibody drug conjugates, multi-specifics, drug combinations, enhanced targeting and PKPD, translational studies and immunotherapy, is being held at the Molecular Med TRI-CON 2012 on Feb. 21-23 at the Moscone in San Francisco.

Moderatored by:  Gary Starling, Ph.D., Director, GPRD Discovery, Oncology Biologics, Abbott Biotherapeutics Corp. Join leading cancer research experts to discuss:

- Development of pre-clinical models to reflect the human tumour
- Pre-clinical parameters that are translatable from animals to humans
- Decision making based on pre-clinical safety and efficacy studies
- Using PD biomarkers to determine dose
- New tools to help translational research
- Phase one safety and tolerability
- Regulatory Concerns

For more information and to view the full agenda visit, http://www.triconference.com/Cancer-Biologics/

The Cancer Biologics conference is one of the program offerings at CHI’s flagship event, the Molecular Medicine Tri-Conference (February 19-23).  This international event features 2 partnering forums, 5 symposia, 18 short courses, and 12 core programs around 4 scientific channels: diagnostics, drug discovery & development, informatics, and cancer. Over 3000 attendees and 150+ sponsors & exhibitors will gather in shared networking functions and in the exhibit/poster hall.

Advance registration discounts are available until January 20, 2012. To view the entire conference agenda and to register, please visit http://www.triconference.com/Cancer-Biologics/

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.
End
Cambridge Healthtech Institute PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share